Immune prognostic implications of PSMD14 and its associated genes signatures in hepatocellular carcinoma

PSMD14 played a vital role in initiation and progression of hepatocellular carcinoma (HCC). However, PSMD14 and its-related genes for the immune prognostic implications of HCC patients have rarely been analyzed. Messenger RNA expression profiles and clinicopathological data were downloaded from The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) database-Liver Hepatocellular Carcinoma (LIHC). Additionally, we used multi-dimensional bioinformatics analysis to construct and validate a PSMD14-based immune prognostic signature (including RBM45, PSMD1, OLA1, CCT6A, LCAT and IVD) for HCC prognosis prediction. Patients in the high-risk group shown significantly poorer survival than patients in the low-risk group. Calibration curves confirmed the good consistency between the clinical nomogram prediction and the actual observation. Gene set enrichment analyses (GSEA) revealed several significantly enriched pathways, which might help explain the underlying mechanisms. Besides, the rt-PCR further validates the expression of seven immune genes in HCC cells. Our study identified a novel PSMD14-based signature for HCC prognosis prediction, it provided new potential prognostic biomarkers and therapeutic targets for immunotherapy of HCC.

Automated summary

The study identified a PSMD14-based immune prognostic signature for predicting the prognosis of HCC patients, providing potential new prognostic biomarkers and therapeutic targets for immunotherapy of HCC. Patients in the high-risk group had significantly poorer survival compared to those in the low-risk group, and calibration curves confirmed the accuracy of the predictive model.